News

EC approves BeOne’s Tevimbra for nasopharyngeal carcinoma
BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...
Agence France-Presse2d
European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...
Mid-Day3d
Here's why cancer treatments may trigger serious side-effects, according to a study
The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...
Hidden role of 'cell protector' protein opens cancer treatment possibilities
Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...
News-Medical.Net4d
Landmark discovery reshapes understanding of key cancer protein MCL-1
Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer treatments are causing serious side effects, and offers ...